A recent study published in the Journal of Neurology showed that patients with acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) experience greater improvement of physical function and higher quality of life when they start targeted immunotherapy within 24 months of diagnosis. By analyzing patient data from several German university hospitals, researchers found that this early start leads to faster and more lasting relief than waiting longer to escalate treatment.
“These results support the concept of a time-sensitive therapeutic window during which targeted intervention may be most effective,” said the study’s authors. If the disease isn’t controlled early, chronic immune activity can cause permanent damage to the motor endplate, the bridge where nerves tell muscles to move. Starting targeted treatments, such as complement C5 inhibitors or neonatal Fc receptor (FcRn) antagonists, earlier on may stabilize the condition before the immune system’s attack becomes too complex and harder to manage.
In this study, 153 patients were followed to see how the timing of their therapy affected their disease burden. The patients were divided into two groups: 36 who started add-on therapy within 24 months of diagnosis, and 17 who started later on.
The results revealed a meaningful difference between the two groups: patients who escalated their therapy early saw their Myasthenia Gravis Activities of Daily Living (MG-ADL) scores, which track daily challenges like breathing and swallowing, drop by an average of 4.2 points after six months. By comparison, those who waited longer saw only a 1.5-point improvement. This numerical gap represents a significant shift in a patient’s reality, often marking the difference between struggling with basic household chores and feeling much more capable in their daily life.
This positive trend extended to patient well-being as well. Patients in the early-treatment group reported quality-of-life improvements that were nearly double those of the late-start group. In addition to feeling better, these patients reduced their daily prednisone dose by more than 40% within six months.
Since both groups began the study with comparable symptom severity, the findings indicate that starting treatment earlier, rather than just having a milder case of MG, played a key role in the better results observed.
Learn more about MG treatment and care
The study’s authors noted that even though traditional immunosuppressants work for many, some patients still struggle with persistent symptoms, sudden flares or the side effects of long-term medication. They also noted that their findings are consistent with other recent studies, such as the 2025 study by He et al., which also demonstrated that early initiation of targeted therapy leads to superior clinical improvement. They noted that further research is needed to confirm these results and help clinicians define exactly which patient profiles will benefit most from early treatment intensification.
Sign up here to get the latest news, perspectives, and information about MG sent directly to your inbox. Registration is free and only takes a minute.
